推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

Cancer Communications 期刊收藏夹

欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此反馈;如有合作推广需求,请点此洽谈

按期刊名首写字母查看 CANCER COMMUN最新评论:我也想问这个问题~ 用wiley投稿的~ 投稿之后就是under review,2周过去了`~~还是这个状态,在思考要不要催~ 官网不是说投稿到第1个... (2025-07-02)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
近期推荐:
全流程投稿协助套餐服务
SCI论文AI润色+人工QC服务
Springer Nature特刊征稿
爱思唯尔研究者学院:从初稿到接收 全程赋能
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


Cancer Communications期刊基本信息Hello,您是该期刊的第71676位访客

基本信息 登录收藏
期刊名字Cancer CommunicationsCancer Communications

CANCER COMMUN
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
7.0
54人评分
我要评分

声誉
8.1

影响力
6.1

速度
7.0

期刊ISSN2523-3548
蝌蝌APP,让您与同行交流更轻松
立即下载
2024-2025最新影响因子
(数据来源于搜索引擎)
24.9 点击查看影响因子趋势图
实时影响因子 截止2025年5月19日:24.935
2024-2025自引率1.20%点击查看自引率趋势图
五年影响因子22.2
JCI期刊引文指标 3.67
h-index 暂无h-index数据
CiteScore
2025年最新版
CiteScoreSJRSNIPCiteScore排名
36.506.4034.593
学科分区排名百分位
大类:Medicine
小类:Oncology
Q110 / 415
大类:Medicine
小类:Cancer Research
Q17 / 233

期刊简介
Cancer Communications is an open access, peer-reviewed online journal that aims to publish significant advances across the full specturm of cancer research spanning basic, clinical, and translational work. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics. Article types include Original Article,Review, Commentary, Research Highlight, Letter to the Editor, News and Views, Guideline and Consensus, Short Report, Study protocol, Correspondence and Editorial.

Cancer Communications是一本开放获取、同行评议的在线期刊,旨在发表关于跨越基础、临床和转化工作的全领域癌症研究重大进展情况的文章。该期刊欢迎有关临床试验、流行病学、分子和细胞生物学以及遗传学的稿件。文章类型包括原创文章、综述、评论、研究重点、新闻和观点、指南、简短报告、研究方案、通信和社论。
期刊官方网站https://onlinelibrary.wiley.com/journal/25233548
期刊投稿格式模板
VIP专享
Word版格式模板 LaTeX版格式模板
此模板来自于期刊/出版社官网。开通VIP可免费下载,并享1w+期刊模板资源。
此模板来自于期刊/出版社官网。开通VIP可免费下载,并享1w+期刊模板资源。
期刊投稿网址https://mc.manuscriptcentral.com/cac2
期刊语言要求Language
Manuscripts must be written in American English and be grammatically and linguistically correct. Authors should seek assistance with style, grammar and vocabulary if necessary. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Cancer Communications的语言要求,还能让Cancer Communications编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Cancer Communications编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问Yes
OA期刊相关信息
文章处理费:需要( USD2800; GBP2100; EUR2400; )
文章处理费豁免:查看说明
其他费用:没有
期刊主题关键词:clinical trials、epidemiology、cellular biology、cancer、molecular biology、genetics
相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
通讯方式111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774
出版商Wiley
涉及的研究方向Biochemistry, Genetics and Molecular Biology-Cancer Research
出版国家或地区PEOPLES R CHINA
出版语言English
出版周期Monthly
出版年份2018
年文章数 49点击查看年文章数趋势图
Gold OA文章占比82.80%
研究类文章占比:
文章 ÷(文章 + 综述)
61.22%
WOS期刊JCR分区
2024-2025年最新版
WOS分区等级:1区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ112/326
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ114/326
中国科学院《国际期刊预警
名单(试行)》名单
2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院期刊分区
2025年3月最新升级版
点击查看中国科学院期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 4区1区3区
ONCOLOGY
肿瘤学
1区2区1区
中国科学院期刊分区
2023年12月升级版
大类学科小类学科Top期刊综述期刊
医学 2区1区3区
ONCOLOGY
肿瘤学
3区4区2区
中国科学院期刊分区
2022年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 1区1区1区
ONCOLOGY
肿瘤学
2区1区1区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
中科院的全球OA期刊索引(OAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2523-3548%5BISSN%5D
平均审稿速度网友分享经验:
4 Weeks
平均录用比例网友分享经验:
版面费/APC文章处理费信息
文章处理费:需要( USD2800; GBP2100; EUR2400; )
文章处理费豁免:查看说明
其他费用:没有
LetPub提供文章处理费(APC)支持服务,可以用人民币支付版面费啦!
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在Cancer Communications顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
提交文稿
期刊常用信息链接
同领域相关期刊 Cancer Communications期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 Cancer Communications中国科学院期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
Cancer Communications上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CELLULAR ONCOLOGY08.30
    Translational Oncology418.60
    Journal of Gastric Cancer225.30
    Frontiers in Oncology606.90
    Advances in Cancer Biology Metastasis05.20
    International Journal of Medical Biochemistry00.60
    Critical Reviews in Oncogenesis02.00
    Clinical and Experimental Morphology01.00
    Molecular and Cellular Oncology02.60
    中国科学院期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE766559
    BIOMATERIALS628154
    BIOMEDICINE & PHARMACOTHERAPY623193
    JOURNAL OF ETHNOPHARMACOLOGY621943
    COMPUTERS IN BIOLOGY AND MEDICINE608086
    Frontiers in Pharmacology593686
    Frontiers in Immunology587010
    Frontiers in Oncology524369
    PHYTOMEDICINE502179
    COLLOIDS AND SURFACES B-BIOINTERFACES480443
  •  

    Cancer Communications Cancer Communications
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

    Author: Lao, Mengyi; Zhang, Xiaozhen; Li, Zejun; Sun, Kang; Yang, Hanshen; Wang, Sicheng; He, Lihong; Chen, Yan; Zhang, Hanjia; Shi, Jiatao; Xu, Daqian; Liang, Tingbo; Bai, Xueli
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70038
        PubMed      DOI
    2.Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma

    Author: Zhu, Jinghan; Xiong, Yixiao; Zhang, Yuxin; Liang, Huifang; Cheng, Kun; Lu, Yuanxiang; Cai, Guangzhen; Wu, Yang; Fan, Yunhui; Chen, Xiaoping; Zhu, Hong; Ding, Zeyang; Zhang, Wanguang
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70036
        PubMed      DOI
    3.First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial

    Author: Cheng, Ying; Zhang, Shuang; Han, Liang; Wu, Lin; Chen, Jun; Zhao, Peiyan; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Zimina, Anastasia; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Yu, Haoyu; Li, Jing; Yang, Fang; Yang, Xinyi; Ling, Chen; Wang, Qingyu; Shan, Yongqiang; Zhu, Jun
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70032
        PubMed      DOI
    4.Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial

    Author: Song, Yu; Wang, Yingjiao; Cao, Xi; Xu, Ying; Zhou, Yidong; Sun, Qiang; Shen, Songjie
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70041
        PubMed      DOI
    5.Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47

    Author: Zhang, Jie; Zhang, Chen; Zang, Ruichen; Chen, Weiwu; Guo, Yining; Jiang, Haofei; Le, Jing; Wang, Kunyu; Fan, Haobo; Wang, Xudong; Mo, Sisi; Gao, Peng; Guo, Wenhao; Jiang, Xinrong; Gao, Fengbin; Jiang, Junming; Zheng, Juyan; Chen, Yuxing; Chen, Yicheng; Yu, Yanlan; Ding, Guoqing
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70040
        PubMed      DOI
    6.Ubiquitination in cancer: mechanisms and therapeutic opportunities

    Author: Zhu, Susi; Zhang, Xu; Liu, Waner; Zhou, Zhe; Xiong, Siyu; Li, Jie; Chen, Xiang; Peng, Cong
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70044
        PubMed      DOI
    7.Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination

    Author: Mao, Xianhua; Cheung, Ka-Shing; Tan, Jing-Tong; Mak, Lung-Yi; Lee, Chi-Ho; Cheng, Ho Ming; Hui, Rex Wan-Hin; Chan, Esther Wai Yin; Yu, Philip Leung-Ho; Yuen, Man-Fung; Leung, Wai K.; Seto, Wai-Kay
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70028
        PubMed      DOI
    8.Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor

    Author: Cai, Wenpeng; Fan, Tao; Xiao, Chu; Deng, Ziqin; Liu, Yixiao; Li, Chunxiang; He, Jie
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70027
        PubMed      DOI
    9.Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

    Author: Chen, Si-Yuan; Xu, Peng-Peng; Feng, Ru; Cui, Guo-Hui; Wang, Li; Cheng, Shu; Mu, Rong-Ji; Zhang, Hui-Lai; Wei, Xiao-Lei; Song, Yong-Ping; Ding, Kai-Yang; Dong, Li-Hua; Zhu, Zun-Min; Yang, Shen-Miao; Wang, Xin; Liu, Ting-Bo; Hu, Jian-Da; Zheng, Xiao-Yun; Bai, Ou; Xu, Jing-Yan; Huang, Liang; Sang, Wei; Shi, Ke-Qian; Zhou, Fan; Li, Fei; Liang, Ai-Bin; Zhou, Hui; Hao, Si-Guo; Huang, Hong-Hui; Xu, Bin; Qian, Wen-Bin; Li, Cai-Xia; Li, Zhi-Ming; Wu, Chong-Yang; Wang, Xiao-Bo; Shi, Wen-Yu; Wang, Shu-Ye; Tian, Yu-Yang; Zhang, Xi; Zhou, Ke-Shu; Cui, Li-Juan; Liu, Hui; Tan, Huo; Leng, Qing; Zhao, Dong-Lu; Niu, Ting; Zhao, Wei-Li
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70033
        PubMed      DOI
    10.N6-methyladenosine-regulated exosome biogenesis orchestrates an immunosuppressive pre-metastatic niche in gastric cancer peritoneal metastasis

    Author: Li, Song; Zhou, Jianyuan; Wang, Shuang; Yang, Qian; Nie, Shulun; Ji, Chunwang; Zhang, Xue; Li, Shuhan; Zhou, Xuanyu; Chu, Jiahui; Wu, Xuehui; Jiao, Jianqiao; Xu, Ruitao; Xu, Qian; Huang, Miao; Wang, Qiushi; Dou, Liliang; Hu, Qinqin; Jiang, Fan; Dai, Xin; Nan, Zhaodi; Song, Xinyu; Zhang, Di; Liu, Lian
    Journal: CANCER COMMUNICATIONS. 2025; Vol. , Issue , pp. -. DOI: 10.1002/cac2.70034
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS1441154.20
    NATURE REVIEWS DRUG DISCOVERY289181.80
    Kidney International Supplements2046.20
    Kidney International Supplements2446.20
    LANCET70087.60
    Nature Reviews Clinical Oncology127114.50
    NEW ENGLAND JOURNAL OF MEDICINE93396.40
    NATURE REVIEWS CANCER396103.80
    World Psychiatry6174.00
    World Psychiatry7074.00
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS1441154.20
    NATURE REVIEWS MICROBIOLOGY250106.40
    NATURE REVIEWS DRUG DISCOVERY289181.80
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386150.90
    LANCET70087.60
    Nature Reviews Materials61105.50
    Nature Reviews Clinical Oncology127114.50
    NEW ENGLAND JOURNAL OF MEDICINE93396.40
    Nature Reviews Earth & Environment070.00
    NATURE REVIEWS CANCER396103.80
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:
Springer发布AI审稿筛查工具:科研人怎么看?加入讨论 >>

同领域作者分享投稿经验:共236


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2025 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室